Highlights

• The company announced launch of Dapagliflozin tablets in the United States market.
• The product received USFDA approval as bioequivalent to Farxiga for approved indications.
• The launch includes two strengths, 5 mg and 10 mg, targeting diabetes treatment.

Lupin Limited (NSE:LUPIN) announced the launch of Dapagliflozin Tablets, available in 5 mg and 10 mg strengths, in the United States. The launch follows approval of its Abbreviated New Drug Application by the U.S. Food and Drug Administration. The product has been approved as bioequivalent to Farxiga for the indications mentioned in the approved labeling. The development marks an addition to the company’s portfolio in the U.S. pharmaceutical market.

Market Context and Product Positioning

Dapagliflozin is used for the management of type 2 diabetes and related conditions. The launch in the United States positions the company within a competitive generic drug segment, where bioequivalent products aim to provide alternatives to branded therapies. The availability of two dosage strengths aligns with standard treatment requirements and prescribing patterns in the market.

Company Overview and Global Presence

Lupin Limited operates across more than 100 markets with a diversified pharmaceutical portfolio, including branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The company has 15 manufacturing sites and 7 research centers globally, supported by a workforce exceeding 24,000 professionals. Its presence spans multiple therapeutic areas such as respiratory, cardiovascular, anti-diabetic, and central nervous system treatments.

Stock Performance Snapshot

Shares of Lupin Limited were trading at ₹2,319.90, down ₹13.90 or 0.60% on April 13, 2026. The stock has shown mixed performance across different periods, with a 1.75% gain over one week and a marginal 0.22% rise over one month. On a year-to-date basis, the stock has increased by 10.32%, while the one-year return stands at 17.81%. Over three years, the stock has delivered a 245.53% return, indicating significant longer-term movement.

Key Risks

• Pricing pressure in the U.S. generics market affecting revenue realization.
• Regulatory compliance risks related to ongoing USFDA requirements.
• Competition from multiple generic manufacturers for the same molecule.
• Dependence on U.S. market performance for product commercialization outcomes.

Summary

Lupin Limited has launched Dapagliflozin Tablets in the United States following USFDA approval. The product, bioequivalent to Farxiga, expands its presence in the anti-diabetic segment. While the launch adds to its U.S. portfolio, factors such as pricing pressure, competition, and regulatory compliance remain relevant. The stock showed marginal decline in the latest session with varied performance across timeframes.

FAQs

1. What product has Lupin launched in the United States?
   Lupin launched Dapagliflozin Tablets in 5 mg and 10 mg strengths for approved anti-diabetic indications in the U.S.
2. What is Dapagliflozin used for?
   Dapagliflozin is used for managing type 2 diabetes and related cardiovascular and renal conditions as per approved labeling.
3. How has Lupin stock performed recently?
   The stock declined 0.60% in the latest session but has delivered positive returns across one-year and longer-term periods.